Billiontoone, Inc. (NASDAQ:BLLN) Receives $135.29 Average PT from Brokerages

Shares of Billiontoone, Inc. (NASDAQ:BLLN) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $135.2857.

A number of equities research analysts have weighed in on the company. Stifel Nicolaus started coverage on Billiontoone in a report on Monday, December 1st. They issued a “buy” rating and a $145.00 price objective on the stock. Guggenheim assumed coverage on Billiontoone in a report on Tuesday, January 6th. They issued a “buy” rating and a $120.00 price target for the company. Jefferies Financial Group started coverage on Billiontoone in a report on Monday, December 1st. They set a “hold” rating and a $117.00 price objective on the stock. JPMorgan Chase & Co. cut their price objective on Billiontoone from $150.00 to $145.00 and set an “overweight” rating for the company in a research report on Wednesday, December 10th. Finally, William Blair assumed coverage on shares of Billiontoone in a research report on Monday, December 1st. They set an “outperform” rating on the stock.

Billiontoone Trading Down 1.2%

Shares of NASDAQ BLLN opened at $88.61 on Friday. The business’s fifty day moving average is $90.15. Billiontoone has a 1-year low of $80.00 and a 1-year high of $138.70. The firm has a market capitalization of $4.06 billion and a P/E ratio of 886.10.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Tuesday, December 9th. The company reported $0.10 EPS for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.06). The business had revenue of $83.52 million for the quarter, compared to the consensus estimate of $82.86 million.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Rossby Financial LCC purchased a new stake in shares of Billiontoone during the 4th quarter worth approximately $25,000. Wells Fargo & Company MN acquired a new position in Billiontoone during the fourth quarter worth $76,000. Smartleaf Asset Management LLC purchased a new stake in Billiontoone during the fourth quarter worth $80,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in Billiontoone in the fourth quarter valued at $82,000. Finally, Renaissance Capital LLC acquired a new stake in Billiontoone in the fourth quarter valued at $201,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.